Skip to content
Dextroamphetamine
Adderall, Biphetamine, Delcobese, Dexedrine, Mydayis, Xelstrym (dextroamphetamine) is a small molecule pharmaceutical. Dextroamphetamine was first approved as Delcobese on 1982-01-01. It is used to treat attention deficit disorder with hyperactivity and narcolepsy in the USA. The pharmaceutical is active against sodium-dependent dopamine transporter and sodium-dependent noradrenaline transporter. In addition, it is known to target trace amine-associated receptor 1.
Download report
Favorite
Top Prescription Drugs
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
mental disordersD001523
Trade Name
FDA
EMA
Dexedrine, Xelstrym (generic drugs available since 2001-01-31, discontinued: Dexampex, Dextrostat, Ferndex)
Combinations
Adderall, Mydayis (generic drugs available since 2001-01-31, discontinued: Biphetamine, Delcobese)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amphetamine aspartate
+
Amphetamine sulfate
+
Dextroamphetamine saccharate
+
Dextroamphetamine sulfate
Tradename
Company
Number
Date
Products
ADDERALL XR 25TakedaN-021303 RX2002-05-22
1 products, RLD
ADDERALL XR 5TakedaN-021303 RX2002-05-22
1 products, RLD
ADDERALL XR 15TakedaN-021303 RX2002-05-22
1 products, RLD
ADDERALL XR 10TakedaN-021303 RX2001-10-11
1 products, RLD
ADDERALL XR 20TakedaN-021303 RX2001-10-11
1 products, RLD
ADDERALL XR 30TakedaN-021303 RX2001-10-11
1 products, RLD, RS
MYDAYISTakedaN-022063 RX2017-06-20
4 products, RLD, RS
Show 7 discontinued
Amphetamine resin complex
+
Dextroamphetamine resin complex
Tradename
Company
Number
Date
Products
BIPHETAMINE 20UCBN-010093 DISCN1982-01-01
1 products
BIPHETAMINE 12.5UCBN-010093 DISCN1982-01-01
1 products
BIPHETAMINE 7.5UCBN-010093 DISCN1982-01-01
1 products
Hide discontinued
Dextroamphetamine
Tradename
Company
Number
Date
Products
XELSTRYMNoven PharmaceuticalsN-215401 RX2022-03-22
4 products, RLD, RS
Dextroamphetamine sulfate
Tradename
Company
Number
Date
Products
DEXEDRINEImpax LaboratoriesN-017078 RX1982-01-01
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
adderallNew Drug Application2022-10-24
dexedrineNew Drug Application2019-06-17
dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfateANDA2023-06-14
mydayisNew Drug Application2021-01-06
xelstrymNew Drug Application2022-12-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
attention deficit disorder with hyperactivityEFO_0003888D001289F90
narcolepsyEFO_0000614D009290G47.4
Agency Specific
FDA
EMA
Expiration
Code
DEXTROAMPHETAMINE, XELSTRYM, NOVEN PHARMS INC
2025-03-22NP
AMPHETAMINE ASPARTATE / AMPHETAMINE SULFATE / DEXTROAMPHETAMINE SACCHARATE / DEXTROAMPHETAMINE SULFATE, MYDAYIS, TAKEDA PHARMS USA
2023-03-13PED
Patent Expiration
Patent
Expires
Flag
FDA Information
Dextroamphetamine, Xelstrym, Noven Pharms Inc
115595012042-01-06DP
94569932033-10-24DPU-3340
94747222033-10-24DP
85919412025-10-07DP
86328022025-10-07DP
90343702025-10-07DP
Amphetamine Aspartate / Amphetamine Sulfate / Dextroamphetamine Saccharate / Dextroamphetamine Sulfate, Mydayis, Takeda Pharms Usa
88461002029-08-24DP
91738572026-05-12U-2025
69137682023-05-24DPU-2025
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06B: Psychostimulants, agents used for adhd and nootropics
— N06BA: Centrally acting sympathomimetics
— N06BA02: Dexamfetamine
HCPCS
Code
Description
S0160
Dextroamphetamine sulfate, 5 mg
Clinical
Clinical Trials
82 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Attention deficit disorder with hyperactivityD001289EFO_0003888F90—755419
Substance-related disordersD019966EFO_0003890F13—2—114
Conduct disorderD019955EFO_0004216F91———2—2
Cognitive dysfunctionD060825G31.84—111—2
ObesityD009765EFO_0001073E66.9———1—1
Glucose intoleranceD018149HP_0000833R73.03———1—1
MotivationD009042———1—1
DeceptionD008192———1—1
Alzheimer diseaseD000544EFO_0000249F03———1—1
DementiaD003704F03———1—1
Show 3 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cocaine-related disordersD019970F148112—120
Multiple sclerosisD009103EFO_0003885G35—22——2
GliomaD005910EFO_0000520——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F20—1——23
NarcolepsyD009290EFO_0000614G47.421———3
Opioid-related disordersD009293EFO_0005611F11—1——12
AnhedoniaD059445R45.8411———2
Bipolar disorderD001714EFO_0000289F30.911———2
StrokeD020521EFO_0000712I63.9—2———2
Short-term memoryD008570EFO_0004335—1———1
AffectD000339—1———1
GamblingD005715F63.0—1———1
Idiopathic hypersomniaD020177G47.11—1———1
Show 3 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—5————5
Major depressive disorderD003865EFO_0003761F221———12
HemodynamicsD0064391————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Psychotic disordersD011618F20.81————11
AlcoholismD000437EFO_0003829F10.1————11
Obsessive-compulsive disorderD009771EFO_0004242F42————11
Tobacco use disorderD014029F17————11
Marijuana abuseD002189EFO_0007191F12————11
Morbid obesityD009767EFO_0001074————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDEXTROAMPHETAMINE
INNdexamfetamine
Description
(S)-amphetamine is a 1-phenylpropan-2-amine that has S configuration. It has a role as a neurotoxin, an adrenergic uptake inhibitor, a dopaminergic agent, a sympathomimetic agent, a dopamine uptake inhibitor and an adrenergic agent. It is an enantiomer of a (R)-amphetamine.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@H](N)Cc1ccccc1
Identifiers
PDB4XP9
CAS-ID51-64-9
RxCUI3288
ChEMBL IDCHEMBL612
ChEBI ID4469
PubChem CID5826
DrugBankDB01576
UNII IDTZ47U051FI (ChemIDplus, GSRS)
Target
Agency Approved
SLC6A3
SLC6A3
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
SLC6A3
Gene synonyms
DAT1
NCBI Gene ID
6531
Protein name
sodium-dependent dopamine transporter
Protein synonyms
DA transporter, dopamine transporter 1, solute carrier family 6 (neurotransmitter transporter), member 3, solute carrier family 6 (neurotransmitter transporter, dopamine), member 3, Solute carrier family 6 member 3
Uniprot ID
Q14996
Mouse ortholog
Slc6a3 (13162)
sodium-dependent dopamine transporter (Q9R1I2)
Alternate
TAAR1
TAAR1
Organism
Homo sapiens
Gene name
TAAR1
Gene synonyms
TA1, TAR1, TRAR1
NCBI Gene ID
134864
Protein name
trace amine-associated receptor 1
Protein synonyms
trace amine receptor 1
Uniprot ID
Q96RJ0
Mouse ortholog
Taar1 (111174)
trace amine-associated receptor 1 (Q923Y8)
Variants
Clinical Variant
No data
Financial
Mydayis - Shire
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Adderall - Shire
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Adderall - Takeda
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,004 documents
View more details
Safety
Black-box Warning
Black-box warning for: Adderall, Dexedrine, Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate, Mydayis, Xelstrym
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
108,223 adverse events reported
View more details